Best Practices in Developing Proprietary Names for Human Prescription Drug Products

On 9 December 2020 the FDA Announced the Availability of the Final Guidance for Industry.

FDA is issuing this guidance to help sponsors of human prescription drug products develop proprietary names for those products. This guidance describes best practices to help minimize proprietary name-related medication errors and otherwise avoid adoption of proprietary names that contribute to violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its implementing regulations. It also describes the framework FDA uses in evaluating proposed proprietary names that is also available to sponsors to use before submitting names for FDA review if they wish. This guidance does not address the designation of established names or proper names.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /